Oncology

Latest News

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

By Rose McNulty

May 14th 2025

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

chemotherapy | Image credit: Penn Medicine

December 19th 2024

The High Cost of Shortages of Low-Cost Chemotherapy

Interview by Mary Caffrey

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

December 17th 2024

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com

December 16th 2024

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

Highlights From COA 2024

December 14th 2024

ICYMI: Highlights From COA 2024

The Community Oncology Alliance (COA) meetings featured expert discussions around the evolving landscape of oncology care and health care reform.

AJMC

December 13th 2024

Cost-Effectiveness of a Multicancer Early Detection Test in the US

Anuraag R. Kansal, PhD Ali Tafazzoli, PhD Alissa Shaul, MPH Ameya Chavan, MS Weicheng Ye, MPH Denise Zou, MA A. Mark Fendrick, MD

Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening.

Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program

December 12th 2024

Improving Access to Nivolumab by Lowering Age Restrictions in Clinical Trial

Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program, member of the Lymphoma Research Foundation’s Scientific Advisory Board, shares findings on innovative strategies to improve access to new therapies in pediatric cancer.

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health

December 10th 2024

How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).

Person fills prior authorization form - Maksim Shchur - stock.adobe.com.jpeg

December 4th 2024

Prior Authorization Delays Cause Serious Harm to Patients With Cancer

Insurance hurdles worsen delays, force abandoned treatments, and result in hospitalizations and deaths, radiation oncologists report nationwide.

Highlights From ACCC Annual Meeting & Cancer Center Business Summit

December 4th 2024

ICYMI: Highlights From ACCC Spring 2024

Our top content from the Spring Association of Cancer Care Centers (ACCC) Annual Meeting & Cancer Center Business Summit featured topics on health care worker retention, advancements in precision medicine, and more!

Sandra Cuellar, PharmD

November 29th 2024

From Data to Dialogue: Transforming Oncology With Real-World Evidence

Skylar Jeremias

Sandra Cuellar, PharmD, from the University of Illinois Chicago, highlights the critical role of real-world data in shaping reimbursement models for oncology therapies and emphasizes the growing importance of patient-centered care through shared decision-making, precision medicine, and patient-reported outcomes.

FDA approval. | Image Credit: syahrir - stock.adobe.com

November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Non-Hodgkin Lymphoma | Image Credit: © MQ-Illustrations - stock.adobe.com

November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser

Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).

Kasey Bond, MPH, Perlmutter Cancer Center

November 17th 2024

Uniting to Support Patients With Cancer Beyond Treatment

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

FDA Approval-BHM-stock.adobe.com

November 14th 2024

FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions

Giuliana Grossi

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.

Oscar B. Lahoud, MD, NYU Langone Health

November 13th 2024

Bridging Cancer Care Gaps and Overcoming Medical Mistrust

In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.

AJMC

November 13th 2024

How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care

Arthur S. Hong, MD, MPH Beverly Kyalwazi, MD Ethan A. Halm, MD, MPH, MBA D. Mark Courtney, MD, MSCI John W. Sweetenham, MD Navid Sadeghi, MD, MSPH John V. Cox, DO, MBA Simon J. Craddock Lee, PhD, MPH

Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.

doc reviewing lung report | Image Credit: © meeboonstudio - stock.adobe.com

November 8th 2024

Research Reveals Common Types of Rituximab-Induced Interstitial Lung Disease in Patients With Lymphoma

Karen Jacobson-Sive

Rituximab-induced interstitial lung disease in patients with non-Hodgkin lymphoma presents with distinct clinical characteristics and bronchoalveolar lavage results.

Karen Winkfield, MD, PhD

November 7th 2024

Adapting Cancer Treatment for Survivorship and Precision Care

The American Journal of Managed Care® and Vanderbilt University Medical Center partnered on a recent Institute for Value-Based Medicine® event, which had the theme, “Bringing the Future to the Present in Cancer Care.”

Fish oil supplements in fish shape | Image credit: zilvergolf – stock.adobe.com

November 5th 2024

High Omega-3, Omega-6 Levels May Lower Cancer Risk

Hayden E. Klein

Higher levels of these fatty acids may reduce the risk of developing several types of cancer, though certain risks, such as a potential link to prostate cancer, highlight the complexity of their impact on overall cancer risk.

Cancer disparities | Image credit: Yurii Kibalnik - stock.adobe.com

November 4th 2024

Disparities in Cancer Mortality Among Asian Americans and Pacific Islanders

Despite an overall decline in cancer-specific mortality, death rates from certain cancer types are rising among Asian American and Pacific Islander populations.

Smoking | Image credit: ehabeljean - stock.adobe.com.jpg

October 31st 2024

Early Smoking Cessation Treatment After Cancer Diagnosis Improves Survival

Smoking after a cancer diagnosis increases risk of mortality and a second cancer, study finds.

Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada

October 28th 2024

Transforming Oncology Care With AI-Driven Insights

Leveraging Microsoft’s Azure OpenAI, Ontada streamlines oncology data analysis, reducing processing times by 85% to support clinical decisions and improve patient care for over 3000 oncologists across 30 states, according to Wanmei Ou, PhD, vice president of product, data analytics, and artificial intelligence (AI) at Ontada.

Vinayak Venkataraman, MD

October 24th 2024

Sarcoma Care: Biomarker Advancements Shape the Future

At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."

Gut health concept | Image credit: faithie - stock.adobe.com

October 23rd 2024

Ixcela, Roper St. Francis Healthcare Launch Innovative Cancer Support Program to Improve Treatment Outcomes

A pioneering program targeting gut microbiome health significantly reduces cancer treatment side effects, enhancing patient well-being and resilience.

Glenn Balasky, executive director of the Rocky Mountain Cancer Center.

October 21st 2024

Bridging the Digital Divide of Rural Cancer Care With Telehealth

Cameron Santoro

Glenn Balasky, executive director of Rocky Mountain Cancer Centers, emphasizes the need for government support to sustain telehealth and suggested a hybrid model combining centralized high-tech care with remote monitoring to address the challenges of providing innovative care in rural settings.

Hari Deshpande, MD, Yale Cancer Center

October 17th 2024

Elevating Sarcoma Outcomes Through Value-Based Care

At our recent Institute for Value-Based Medicine® event in Boston, Hari Deshpande, MD, Yale Cancer Center, presented on predictive biomarkers in sarcomas.

Advancing health equity can be achieved through community engagement | image credit: Andrii - stock.adobe.com

October 16th 2024

Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity

Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.

Screenshot of an interview with Terry Keys

October 16th 2024

Combatting Misconceptions of Clinical Trials to Improve Patient Participation

Laura Joszt, MA

There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.

Screenshot of an interview with Naoto Ueno, MD, PhD

October 15th 2024

Creating Equitable Cancer Care for Americans of Asian and Pacific Islander Heritage

Alexandra Gerlach Laura Joszt, MA

Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.

Medicinal cannabis | image: NJ.gov

October 14th 2024

Navigating the Complexities of Cancer Care: Cannabis and Cost Considerations

Laura Joszt, MA

<1 2 3 4 5 6 7 8

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions